Working… Menu

Angiogenic and EGFR Blockade With Curative Chemoradiation for Advanced Head and Neck Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00140556
Recruitment Status : Completed
First Posted : September 1, 2005
Results First Posted : August 31, 2011
Last Update Posted : January 18, 2013
Genentech, Inc.
OSI Pharmaceuticals
Information provided by (Responsible Party):
David M. Brizel, MD, Duke University

Brief Summary:

Radiotherapy (RT) with concurrent chemotherapy represents the state of the art in curative intent treatment for locally advanced squamous carcinoma of the head and neck. Tumor hypoxia and high levels of angiogenesis (blood vessel formation) are associated with treatment failure. Preclinical models reveal that radiotherapy itself may induce tumor secretion of vascular endothelial growth factor (VEGF). Curability may consequently be reduced by multiple mechanisms. Over-expression of epidermal growth factor receptor (EGFR) also occurs commonly and increases the risk of treatment failure. The addition of EGFR blockade to RT alone increases the chance of a cure. Concurrent VEGF and EGFR blockade could be synergistic with one another and improve the effectiveness of concurrent chemoradiation for advanced head and neck cancer.

This study will add angiogenic and epidermal growth factor receptor (EGFR) blockade into an established program of curative intent concurrent chemoradiation for locally advanced head and neck cancer. The safety and effectiveness of delivering the drugs bevacizumab and Tarceva in conjunction with twice daily irradiation and concurrent cisplatin (CDDP) chemotherapy will be determined.

Condition or disease Intervention/treatment Phase
Head and Neck Cancer Pharynx Cancer Radiation: Chemoradiotherapy Drug: Cisplatin Drug: Bevacizumab Drug: Erlotinib Early Phase 1

Detailed Description:

Pre Radiation Period:

  • Bevacizumab (10 mg/kg) on days -14 and 0, or
  • Tarceva (100 mg) daily from -14-0, or
  • Bevacizumab (10 mg/kg) on days -14 and 0; Tarceva (100 mg) daily from -14-0

Chemoradiation Period:

  • Radiotherapy may be delivered via conventional 2-D, conformal 3-D, or intensity modulated (IMRT) technique as is clinically indicated. Radiotherapy and CDDP doses will be delivered uniformly to all treatment cohorts:

    • RT: 1.25 Gy BID M-F with a 6 hour interfraction interval
    • Treatment break during week 4. Total dose 70 Gy/7 weeks
    • CDDP: 33 mg/m2 M-W on weeks 1 and 5 of RT with standard DUMC hydration and anti-emetic regimens
  • Bevacizumab (10mg/kg): Monday of weeks 1, 3, 5, 7 of RT
  • Tarceva (100 mg): Daily for weeks 1-7 of treatment, except for days receiving CDDP

Safety Assessments:

  • Baseline and then weekly assessments of blood pressure and urine protein : creatinine ratios during lead in and chemoRT phases of treatment
  • Baseline carotid Doppler ultrasound evaluation
  • Carotid Doppler ultrasound evaluation 1 month post-chemoRT

Efficacy Assessments:

  • MR Imaging/Spectroscopy to be done at baseline, end of lead-in phase, end of week 1 of chemoRT, and end of chemoRT
  • Angiogenic and EGFR related cytokines. Specifically, blood samples will be obtained to assay levels of VEGF, b-FGF, IL-8, D-dimer, EGF, TGF. These samples will be obtained on the same dates as the MR studies with an additional set of samples obtained at the midpoint of the lead in phase of treatment (day -7).

Clinical Assessments:

  • All patients will undergo a minimum of once weekly interval history and physical examination including fiberoptic pharyngoscopy/laryngoscopy when indicated in the Department of Radiation Oncology to monitor for side effects and response to treatment as per standard routine for the care of patients with head and neck cancer.
  • Patient compliance with Tarceva administration monitored via diary MRI/MRS (Magnetic Resonance Spectroscopy) DE-MRI

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 28 participants
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Concurrent Angiogenic and EGFR Blockade in Conjunction With Curative Intent Chemoradiation for Locally Advanced Head and Neck Cancer
Study Start Date : August 2005
Actual Primary Completion Date : May 2009
Actual Study Completion Date : April 2010

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: ChemoRadiotherapy
Radiation Therapy concurrent with cisplatin chemotherapy, Avastin and Tarceva
Radiation: Chemoradiotherapy
External beam radiation daily (M-F)

Drug: Cisplatin
Cisplatin week 1 and 5 of radiation

Drug: Bevacizumab
Bevacizumab (Avastin) day 1 of weeks 1, 3, and 5 of radiation
Other Name: Avastin

Drug: Erlotinib
Erlotinib daily during radiation
Other Name: Tarceva

Primary Outcome Measures :
  1. Tumor Resolution [ Time Frame: Within 30 days of completing RT ]
    Complete response (resolution) of tumor on clinical exam.

Secondary Outcome Measures :
  1. Local Regional Control [ Time Frame: 1 yr following chemoradiation ]
  2. Failure Free Survival [ Time Frame: 3 yrs ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Locally advanced squamous carcinoma of the head and neck (AJCC stages II/IV, M0, and excluding T1N1 and T1N2) undergoing curative intent concurrent chemoradiation.
  • Previous treatment of any sort other than a biopsy is not allowed.
  • Eligible anatomic sites:

    • oral cavity
    • oropharynx
    • hypopharynx
    • supraglottic
    • glottic larynx
  • KPS > 60

Exclusion Criteria:

  • Nasopharynx primary
  • History of malignancy other than basal cell skin cancer.
  • History of claudication, bleeding, or thromboembolic disorders. Patients receiving heparin or Coumadin therapy are ineligible.
  • Primary tumor or lymph node encasement of the carotid artery
  • Blood pressure of >150/100 mmHg
  • Unstable angina
  • New York Heart Association (NYHA) Grade II or greater congestive heart failure
  • History of myocardial infarction within 6 months
  • History of stroke within 6 months
  • Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 0; anticipation of need for major surgical procedure during the course of the study.
  • Minor surgical procedures, fine needle aspirations, or core biopsies within 7 days prior to Day 0
  • Pregnant (positive pregnancy test) or lactating
  • Urine protein : creatinine ratio ≥ 1.0 at screening
  • History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to Day 0
  • Serious, non-healing wound, ulcer, or bone fracture
  • AST, ALT, or bilirubin > 1.5 x normal
  • PT or PTT > 1.5 x normal
  • Platelets < 100,000
  • WBC < 2000
  • Hgb < 10
  • Creatinine clearance < 60 mL/hr
  • Refusal to provide written informed consent

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00140556

Layout table for location information
United States, North Carolina
Department of Radiation Oncology; Duke University Medical Center
Durham, North Carolina, United States, 27710
Sponsors and Collaborators
David M. Brizel, MD
Genentech, Inc.
OSI Pharmaceuticals
Layout table for investigator information
Principal Investigator: David M Brizel, MD Department of Radiation Oncology; Duke University Medical Center

Publications of Results:
Other Publications:
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: David M. Brizel, MD, Professor, Radiation Oncology, Duke University Identifier: NCT00140556     History of Changes
Other Study ID Numbers: Pro00008840
7077 ( Other Identifier: Legacy IRB number )
First Posted: September 1, 2005    Key Record Dates
Results First Posted: August 31, 2011
Last Update Posted: January 18, 2013
Last Verified: January 2013
Keywords provided by David M. Brizel, MD, Duke University:
head and neck cancer
targeted therapy
concurrent chemotherapy
pharynx cancer
tonsil cancer
epidermal growth factor
vascular endothelial growth factor
magnetic resonance spectroscopy
cancer of the head and neck
upper aerodigestive tract neoplasms
pharynx neoplasms
Additional relevant MeSH terms:
Layout table for MeSH terms
Head and Neck Neoplasms
Pharyngeal Neoplasms
Neoplasms by Site
Otorhinolaryngologic Neoplasms
Pharyngeal Diseases
Stomatognathic Diseases
Otorhinolaryngologic Diseases
Erlotinib Hydrochloride
Antineoplastic Agents
Antineoplastic Agents, Immunological
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action